Arimixyl 1 - Kalpa Pharmaceuticals

The pharmaceutical company Zeneca introduced anastrozole in the mid-1990s as a breakthrough in anti-estrogen therapy. Unlike tamoxifen, which blocks estrogen at the receptor, anastrozole acts upstream by inhibiting the enzyme aromatase, thereby reducing estrogen production itself. After gaining FDA approval in late 1995, its status was elevated following the results of the ATAC trial, which involved over 9,000 women and proved the drug's effectiveness in post-surgical breast cancer treatment. With these findings, it was rapidly integrated into clinical guidelines for hormone-sensitive cancer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Arimixyl 1 by Kalpa Pharmaceuticals, consult with your doctor or healthcare professional.